CTSG can also activate pro-MMP-9 to cut and release active transforming growth factor β (TGF-β), MMP-13, and RANKL at the tumor-bone interface of osteolytic lesions induced by breast tumors (37). This evidence concerns the gene TGFB1 and neoplasm.